Entrectinib
Brand Name: Rozlytrek
Manufacturer: Roche / Genentech
Indication
Indication:
for the treatment of adult and pediatric patients (12 years of age and older in the US; 1 month and older in the EU) with solid tumors that are NTRK gene fusion-positive.
Specific CRC Subtype: NTRK gene fusion
Stage: IV
Therapy Line: Third-line or later
Health Canada Approval: Approved
pCPA Negotiation Status: Completed
Reimbursed in:
New Search
